Welcome to our dedicated page for Immuneering news (Ticker: IMRX), a resource for investors and traders seeking the latest updates and insights on Immuneering stock.
Immuneering Corporation (Nasdaq: IMRX) is a clinical-stage oncology company developing Deep Cyclic Inhibitors, with a lead focus on atebimetinib, an oral, once-daily MEK inhibitor for MAPK pathway-driven cancers such as pancreatic cancer. This news page aggregates company announcements, clinical data updates, financing news, and other disclosures that Immuneering releases through press statements and regulatory filings.
Readers can find detailed coverage of Immuneering’s clinical trial progress, including Phase 2a data for first-line pancreatic cancer patients treated with atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP). The company has reported updated overall survival, progression-free survival, response rates, and safety findings from a cohort of 34 patients, as well as case studies of patients treated with atebimetinib plus FOLFIRINOX. Immuneering also provides timelines for anticipated milestones such as additional survival data readouts and the planned initiation of a global Phase 3 registrational trial in metastatic pancreatic cancer.
In addition to clinical results, Immuneering’s news flow includes corporate and financial updates such as quarterly financial results, underwritten public offerings of Class A common stock, private placements with institutional investors, and guidance on expected cash runway. Announcements related to index inclusion, such as the company’s expected addition to the Nasdaq Biotechnology Index, and conference presentations at healthcare and scientific meetings are also part of the regular news cycle.
Investors and followers of oncology drug development can use this page to track Immuneering’s disclosures about regulatory interactions with the FDA and EMA, combination trial agreements in non-small cell lung cancer, and intellectual property developments such as the granting of a U.S. composition of matter patent for atebimetinib. Bookmark this feed to monitor how Immuneering’s Deep Cyclic Inhibitor programs and corporate strategy evolve through official company communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology firm, has priced its underwritten offering of 2,727,273 shares of Class A common stock at $11.00 per share, aiming for gross proceeds of $30 million. The proceeds will support the preclinical and clinical development of its product candidates and general corporate purposes. The offering is facilitated through a shelf registration statement filed with the SEC. Jefferies, TD Cowen, and Guggenheim Securities are acting as joint book-running managers. The press release includes forward-looking statements, cautioning that actual results may vary due to economic factors and associated risks.
Immuneering Corporation (Nasdaq: IMRX) presented promising initial data from their Phase 1 trial of IMM-1-104 at the AACR Annual Meeting. This novel therapy targets RAS mutant tumors and demonstrated significant pharmacokinetic (PK) levels, achieving over 2,000 ng/mL with a median half-life of approximately 1.94 hours. The drug was well tolerated, having no dose limiting toxicities (DLTs) or serious adverse events (SAEs) reported. The company indicated an acceleration in the study timeline, with the recommended Phase 2 dose (RP2D) now anticipated in early 2024, earlier than originally expected. Initial pharmacodynamic (PD) results showed over 90% inhibition of pERK in patients, supporting the potential efficacy of IMM-1-104. Further updates on the trial are expected periodically.